Gilead Sciences breaks ground on new manufacturing and technical development site in US
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
Subscribe To Our Newsletter & Stay Updated